uBriGene provides custom cell and gene therapy services, including development, manufacturing, and quality control for advanced therapy medicinal products (ATMPs) such as plasmids, mRNA-LNPs, and viral vectors. The company accelerates the transition from research to clinical application, ensuring regulatory compliance and product integrity throughout the process.
Funding
$27.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The development and manufacturing of advanced therapy medicinal products (ATMPs) like plasmids, mRNA-LNPs, and viral vectors are complex, requiring specialized expertise and facilities. Streamlining the transition from research to clinical application presents challenges in ensuring regulatory compliance, product integrity, and efficient scaling.
Solution
uBriGene provides comprehensive contract research, development, and manufacturing organization (CRDMO) services for cell and gene therapies, accelerating the journey from concept to commercialization. The company offers custom services encompassing development, manufacturing, and quality control for ATMPs, including plasmids, mRNA-LNPs, viral vectors, and cell therapies (CAR-T, CAR-NK, iPSC, MSC). uBriGene leverages technology platforms and GMP facilities to support projects from preclinical studies and IND enabling to commercial manufacturing, ensuring regulatory compliance and product quality at each stage. They also offer analytical development and testing services, as well as ready-to-use cell and gene therapy products available in R&D and GMP grades.
Target Audience
uBriGene serves biotechnology and pharmaceutical companies, research institutions, and other organizations involved in the development and commercialization of cell and gene therapies.
Features
- CDMO services for plasmids, mRNA-LNP, sgRNA, viral vectors (lentivirus, AAV, adenovirus), and cell therapy products (CAR-T, CAR-NK, iPSC, MSC)
- Analytical development and GMP testing services utilizing state-of-the-art technologies and quality infrastructures
- Ready-to-use GMP-grade AAV and LVV helper plasmids with activated Drug Master Files (DMF)
- AAV empty capsids, chromatography purified and extensively characterized
- GFP, GFP-Luciferase, and CD19-CAR lentiviral vectors with chromatography purification and high transduction efficiency
- iPSC generation products, including a highly efficient mRNA-LNP reprogramming cocktail
- Ubrinuclease, a GMP-grade DNA & RNA nuclease for cell and gene therapy and biologics manufacturing